567616

Sodium 4-Phenylbutyrate

A novel anti-neoplastic agent and transcriptional regulator.

• Synonym(s): Sodium 4-Phenylbutyrate, SPB, PBNa, 4PBA, 4-Phenylbutyrate, Na, BCKD Kinase Inhibitor I, Branched-Chain α-Ketoacid Dehydrogenase Kinase Inhibitor I, BDK Inhibitor I
• Empirical Formula (Hill Notation): C₁₀H₁₁NaO₂
• CAS Number: 1716-12-7
• Molecular Weight: 186.18
• MDL number: MFCD00800247
• UNSPSC Code: 41116107
• NACRES: NA.77

Properties

• Quality Level: 100
• assay: ≥98% (HPLC)
• form: solid
• manufacturer/tradename: Calbiochem^®
• storage condition: OK to freeze; desiccated (hygroscopic)
• color: white to slightly yellow
• solubility: water: 10 mg/mL
• shipped in: ambient
• storage temp.: −20°C
• InChI: 1S/C10H12O2.Na/c11-10(12)8-4-7-9-5-2-1-3-6-9;/h1-3,5-6H,4,7-8H2,(H,11,12);/q;+1/p-1
• InChI key: VPZRWNZGLKXFOE-UHFFFAOYSA-M

Description

General description

A novel anti-neoplastic agent and transcriptional regulator. Also acts as an inducer of tumor cytostasis and differentiation. Increases fetal hemoglobin production in vitro and in vivo.

An antineoplastic agent that demonstrates potent differentiating capacity in multiple hematopoietic and solid tumor cell lines. Acts as an inducer of tumor cytostasis and differentiation as well as of peroxisomal proliferation. A more effective inhibitor of histone deacetylase and inducer of histone acetylation than its structural analogs including 2- and 3-phenylbutyrate. Acts as a transcriptional regulator and improve the targeting of δF508-CFTR (cystic fibrosis transmembrane regulator) for ubiquitination and degradation by reducing the expression of HSC70 in epithelial cells. Also, reported to increase fetal hemoglobin production in vitro and in vivo.

Biochem/physiol Actions

Cell permeable: no

Primary Target
Anti-neoplastic agent

Product does not compete with ATP.

Reversible: no

Warning

Toxicity: Standard Handling (A)

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Other Notes

Tso, S.C., et al. 2013. Proc. Natl. Acad. Sci. USA110, 9728.
Ozcan, U., et al. 2006. Science313, 1137.
Carducci, M.A., et al. 2001. Clin. Cancer Res.7, 3047.
Rubenstein, R.C. and Zeitlin, P.L. 2000. Am.J. Physiol. Cell. Physiol.278, C259.
Lea, M.A., et al. 1999. Anticancer Res.19, 1971.
Miller, A.C., et al. 1997. Int. J. Radiat. Biol. 72, 211.
Rubenstein, R.C., et al. 1997. J. Clin. Invest. 100, 2457.
Pineau, T., et al. 1996. Biochem. Pharmacol. 52, 659.
Collins, A.F., et al. 1995. Blood 85, 43.
Lea, M.A., et al. 1995. Anticancer Res.15, 879.
Figg, W.D., et al. 1994. Anticancer Drugs 5, 336.
Liu, L., et al. 1994. J. Invest. Dermatol. 103, 335.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Safety Information

• Storage Class: 11 - Combustible Solids
• wgk_germany: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable